Gd-BOPTA肝胆期门静脉周围高信号与失代偿期肝硬化再代偿
本研究纳入252例失代偿期肝硬化患者,回顾性分析Gd-BOPTA增强MRI肝胆期门静脉周围高信号与再代偿的关系。37例(14.7%)出现该征象,其再代偿概率显著降低(HR 0.17),且该征象与更高MELD-Na评分相关。
要点
- 肝胆期门静脉周围高信号提示失代偿期肝硬化再代偿概率低(HR 0.17,p=0.004)。
- 该征象与更高MELD-Na评分相关(系数2.90,p=0.003)。
- 出现该征象者仅8.1%实现再代偿,需在报告中提示预后不良。
核心结论
- Gd-BOPTA增强MRI肝胆期门静脉周围高信号可识别失代偿期肝硬化中再代偿可能性较低的患者(HR 0.17,95% CI 0.05-0.49,p=0.004)。
研究设计与样本
- 回顾性研究,纳入252例失代偿期肝硬化患者,均在失代偿时接受Gd-BOPTA增强MRI检查。
- 再代偿采用改良Baveno VII标准定义,中位随访44.7个月(四分位距16.9-73.7个月)。
- 采用Cox比例风险回归评估门静脉周围高信号与再代偿的关联,并进行敏感性分析和bootstrap重采样验证稳健性。
关键影像表现/征象
- 252例中37例(14.7%)在Gd-BOPTA增强MRI肝胆期出现门静脉周围高信号征象。
- 出现门静脉周围高信号的患者中仅3例(8.1%)实现再代偿,未出现该征象者再代偿累积发生率显著更高(p=0.0029)。
诊断标准与关键数值
- 门静脉周围高信号与更高MELD-Na评分显著相关(系数2.90,95% CI 1.00-4.81,p=0.003)。
- 门静脉周围高信号独立关联更低再代偿概率(HR 0.17,95% CI 0.05-0.49,p=0.004)。
- 再代偿组与非再代偿组生存曲线差异显著(p<0.0001)。
临床应用与阅片要点
- 肝胆期门静脉周围高信号应作为失代偿期肝硬化MRI报告中的预后相关征象记录。
- 阅片时需在肝胆期观察门静脉周围区域有无条带状高信号。
- 该征象出现提示临床需更积极管理肝功能,预期再代偿可能性低。
局限性
- 回顾性单中心研究,存在选择偏倚可能。
- 门静脉周围高信号征象的判读依赖主观评估,未报告观察者一致性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To determine the association between periportal hyperintensity sign from gadobenate dimeglumine (Gd-BOPTA)-enhanced hepatobiliary phase magnetic resonance imaging (MRI) and the occurrence of recompensation in patients with decompensated cirrhosis.
METHODS: This retrospective study included 252 patients with decompensated cirrhosis who underwent Gd-BOPTA-enhanced MRI at the time of decompensation. The periportal hyperintensity sign in the hepatobiliary phase was documented. Recompensation was defined using modified Baveno VII criteria. Cox proportional hazards regression was used to evaluate the association between the periportal hyperintensity sign and recompensation. Sensitivity analyses and bootstrap resampling were performed to test the robustness of the results. Survival outcomes were explored according to recompensation status.
RESULTS: Of the 252 patients, 37 (14.7%) exhibited the periportal hyperintensity sign. Linear regression revealed that the periportal hyperintensity sign was significantly associated with a higher model for end-stage liver disease (MELD)-Na score (coefficient, 2.90; 95% confidence interval [CI], 1.00-4.81; p = 0.003). Eighty patients (31.7%) achieved recompensation after a median follow-up of 44.7 months (interquartile range, 16.9-73.7 months). Among the 37 patients with the periportal hyperintensity sign, 3 patients (8.1%) achieved recompensation. Periportal hyperintensity was independently associated with a lower probability of recompensation (hazard ratio, 0.17; 95% CI, 0.05-0.49; p = 0.004), and the association was directionally consistent across sensitivity analyses. Patients without the periportal hyperintensity sign demonstrated a significantly higher cumulative incidence of recompensation than those exhibiting the sign (p = 0.0029). Survival curves indicated significant differences between the recompensated and non-recompensated groups (p < 0.0001).
CONCLUSIONS: Periportal hyperintensity sign from Gd-BOPTA-enhanced hepatobiliary phase MRI may help identify patients less likely to achieve recompensation in decompensated cirrhosis.
引用
- Wu, Hao, Xu, et al. Periportal hyperintensity sign on Gd-BOPTA-enhanced hepatobiliary phase MRI identifies patients less likely to achieve recompensation in decompensated cirrhosis. Abdom Radiol (NY). 2026. PMID: 42455326. doi:10.1007/s00261-026-05686-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。